We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Early Warning Biomarker Found for Chronic Kidney Disease

By LabMedica International staff writers
Posted on 18 Nov 2015
A simple blood test for a specific protein can predict a person's chances of developing chronic kidney disease five years before symptoms emerge, thus doing for kidney disease what cholesterol has done for cardiovascular disease. More...


Relatively high plasma levels of the specific protein soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions.

Scientists at Rush University Medical Center (Chicago, IL, USA) and a large team of collaborators, measured plasma suPAR levels in 3,683 persons enrolled in the Emory Cardiovascular Biobank and determined renal function at enrollment. Their mean age was 63 years; 65% were men; and the median suPAR level, 3,040 pg/mL and at subsequent visits in 2,292 persons. The relationship between suPAR levels and the estimated glomerular filtration rate (eGFR) at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 mL per minute per 1.73 m2 of body-surface area) were analyzed.

Serum concentrations of high-sensitivity C-reactive protein (CRP) were determined with the use of a particle-enhanced immunoturbidimetry assay (FirstMark; GenWay Biotech, San Diego, CA, USA) that has a lower limit of detection of 0.03 mg/L. Plasma levels of suPAR were measured with the suPARnostic kit (ViroGates; Birkerød, Denmark), which has a lower limit of detection of 100 pg/mL. The intra-assay variation is 2.75% and the interassay variation is 9.17%.

Of the 2,292 enrollees, 40% of subjects with high suPAR levels, greater than 3,040 ng/mL but no known kidney disease as indicated by, healthy eGFR levels, went on to develop chronic kidney disease over the course of five years. In comparison, only 10% of those with low suPAR levels at baseline developed the disease. Moreover, suPAR was shown to predict eGFR decline in patients with already established earlier stage kidney disease as well. From a cohort of patients with cardiovascular disease, the study divides suPAR levels into four quartiles: normal suPAR: less than 2,373 pg/mL; above normal: 2,373–3,030 pg/mL, high: 3,040–4,020 pg/mL, and very high: above 4,020 pg/mL.

Sanja Sever, PhD, the study's co-first author, said, “What we've shown is that it doesn't matter whether our subjects were black or white. SuPAR was a strong independent predictor of eGFR decline. APOL1 gene polymorphism is a genetic risk factor for renal disease in the black population, but suPAR's power to predict renal disease appeared not be majorly different in black or white patients.” The authors concluded that elevated plasma suPAR levels were associated with incident chronic kidney disease and a more rapid decline in the eGFR in persons with normal kidney function at baseline. The study was published on November 5, 2015, in the New England Journal of Medicine.

Related Links:

Rush University Medical Center 
FirstMark 
ViroGates 



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.